Adiponectin protects against myocardial ischemia–reperfusion injury: a systematic review and meta-analysis of preclinical animal studies

Hongyi Yue,Qunhui Zhang,Senhao Chang,Xinjie Zhao,Mengjie Wang,Wenhua Li
DOI: https://doi.org/10.1186/s12944-024-02028-w
2024-02-19
Lipids in Health and Disease
Abstract:Myocardial ischemia–reperfusion injury (MIRI) is widespread in the treatment of ischemic heart disease, and its treatment options are currently limited. Adiponectin (APN) is an adipocytokine with cardioprotective properties; however, the mechanisms of APN in MIRI are unclear. Therefore, based on preclinical (animal model) evidence, the cardioprotective effects of APN and the underlying mechanisms were explored.
biochemistry & molecular biology,nutrition & dietetics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the protective effect of adipocytokine - adiponectin (APN) on myocardial ischemia - reperfusion injury (MIRI) and its underlying mechanisms. MIRI is a common phenomenon in the treatment of ischemic heart disease, and its treatment methods are currently limited. Although adiponectin has cardioprotective properties, its specific mechanism in MIRI remains unclear. Therefore, based on evidence from animal models, this study aims to explore the cardioprotective effect of APN and the underlying mechanisms. Specifically, this study evaluated the impact of APN on MIRI by means of systematic review and meta - analysis, mainly focusing on the following aspects: - The size of the myocardial infarction area - Hemodynamic indicators, such as left ventricular end - diastolic pressure (LVEDP), the maximum rate of left ventricular pressure rise (+dP/dtmax), the maximum rate of left ventricular pressure decline (-dP/dtmax) and left ventricular ejection fraction (LVEF) - Oxidative stress, apoptosis and inflammation markers Through these studies, the authors hope to reveal how APN alleviates MIRI through anti - inflammatory, anti - apoptotic and antioxidant effects, and explore its possible signaling pathways. This will help accelerate the translation of clinical research and provide a basis for the treatment of MIRI.